Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > More on Reverse Splits

<< Previous

Bullboard Posts

Next >>

Comment by jfm1330on Mar 29, 2022 12:36pm

54 Views

Post# 34555786

RE:RE:RE:More on Reverse Splits

It was stock promotion, investor relations, american analysts coverage and now it's reverse split. Sorry, it's all stuff with no relation to the value creation that will only happen if the have real good scientific and clinical results. There will be no substitute for real good results, no promotion or financial tricks will change that. I understand the frustration, but that's the situation we are in.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec